Primary extranodal diffuse large B-cell lymphoma in the rituximab era: a single center, retrospective analysis

Figures & data

Figure 1. Anatomic distributions in PE-DLBCL.

Table 1. Patient characteristics according to the primary involved site.

Characteristics	GI tract	CNS + Eye	Nose/nasopharynx	Breast	Testis	Bone	Skin	Thyroid gland	FGS
Total	67	62	14	10	7	6	6	6	5
Age, years
Median	62	61	54	45	58	73	54	63	62
Range	19–75	31–74	28–70	28–65	43–52	60–83	52–83	34–91	45–67
Age > 60years	35	34	6	2	3	6	2	3	3
Sex
Male	33	29	6	0	7	3	3	2	0
Female	34	33	8	10	0	3	3	4	5
ECOG status > 1	13	51	2	1	1	4	2	4	1
Elevated LDH	15	17	2	0	3	5	4	3	1
B symptoms	24	7	1	2	1	4	3	2	2
Ann Arbour stage
I + II	53	40	10	8	4	0	0	1	0
III + IV	14	22	4	2	3	6	6	5	5
Lugano stage
I-IIE	53	–	–	–	–	–	–	–	–
IV	14	–	–	–	–	–	–	–	–
IELSG score
0–1	–	15	–	–	–	–	–	–	–
2–3	–	32	–	–	–	–	–	–	–
4–5	–	15	–	–	–	–	–	–	–
Hans classification
GCB	35	16	8	6	4	3	5	2	4
Non-GCB	30	24	6	4	3	3	1	4	1
DE	17	12	4	5	3	2	3	1	4
IPI score
Low	38	–	9	8	4	0	1	3	1
Low-intermediate	14	–	3	2	1	1	2	0	0
High-intermediate	9	–	2	0	0	3	1	2	3
High	6	–	0	0	2	2	2	1	1
Therapy
R-CHOP	58	–	9	7	5	2	4	4	5
R-EPOCH	4	–	5	1	2	0	0	1	0
Chemotherapy only	48	44	11	4	0	3	6	2	3
Chemo+ surgery	19	18	3	6	7	2	0	4	2
CNS prophylaxis	7	–	3	7	4	1	2	0	2
Received ASCT	2	4	0	1	0	0	1	0	1

ECOG, Eastern Cooperative Oncology Group; GCB, germinal centre B-cell; ASCT, autologous hematopoietic stem cell transplantation; DE, double-protein-expression

Figure 2. Clinical outcomes for patients with PE-DLBCL. Overall survival and progression-free survival for patients with PE-DLBCL.

Figure 3. Clinical outcomes for patients with PCNS-DLBCL and PGI-DLBCL. Overall survival (a) and progression-free survival (b) of PCNS-DLBCL patients with and without surgery; Overall survival (c) and progression-free survival (d) of PGI-DLBCL patients with and without surgery.

Figure 4. Clinical outcomes for patients with central nervous system and vitreoretinal involvement. Overall survival (a) of DLBCL patients with central nervous system and vitreoretinal involvement. Progression-free survival (b) of DLBCL patients with central nervous system and vitreoretinal involvement.

Table 2. Risk factors for survival in patients with PE-DLBCL.

	Overall survival				Progression-free survival
Variables	Univariate	Multivariate			Univariate	Multivariate
	P value	HR	95%	P* value	P value	HR	95%	P* value
Male	0.416				0.499
Age > 60	0.127				0.115
Evaluated LDH	0.029			0.090	0.005			0.579
ECOG > 1	0.200				0.147
With B symptom	0.503				0.417
Ann Arbour stage III-IV	0.031			0.869	0.019			0.818
IPI > 2	0.047			0.257	0.152
GCB (reference non-GCB)	0.989				0.997
DE	0.308				0.300
DH	0.018			0.696	0.000			0.883
Not received CR	<0.001	4.659	2.083-10.423	<0.001	<0.001	5.001	2.231-11.209	<0.001
Primary organ	0.641				0.480

DH: double hit; DE: double-protein-expression; * P value was calculated by COX regression and p < 0.05 regarded significant.

Table 3. Risk factors for survival in patients with PGI-DLBCL.

Variables	Overall survival				Progression-free survival
	Univariate	Multivariate			Univariate	Multivariate
	P value	HR	95%	P* value	P value	HR	95%	P* value
Male	0.640				0.678
Age > 60	0.068			0.221	0.093			0.512
Evaluated LDH	<0.001			0.775	<0.001			0.510
Anemia	0.980				0.877
Albumin＜35 g/L	0.355				0.330
ECOG > 1	0.426				0.419
With B symptom	0.042			0.262	0.052			0.617
Lugano stage IV	0.021			0.061	0.015	3.395	1.033-11.162	0.044
IPI > 2	0.043			0.056	0.059			0.641
GCB (reference non-GCB)	0.744				0.700
DE	0.392				0.463
DH	0.012			0.316	<0.001			0.400
Not received CR	0.001	2.555	1.296-5.037	0.007	<0.001	2.304	1.145-4.639	0.019

DH: double hit; DE: double-protein-expression; * P value was calculated by COX regression and p < 0.05 regarded significant.

Table 4. Risk factors for survival in patients with PCNS-DLBCL and PVR-DLBCL.

	Overall survival				Progression-free survival
Variables	Univariate	Multivariate			Univariate	Multivariate
	P value	HR	95%	P* value	P value	HR	95%	P* value
Male	0.652				0.750
Age > 60	0.366				0.552
ECOG > 1	0.868				0.908
Evaluated LDH	0.447				0.537
Elevated protein in CSF	0.003			0.111	0.006	2.738	1.388-4.552	0.048
Multiple lesions	0.528				0.576
Deep brain involvement	0.111				0.076			0.124
No. of comorbidities＞1	0.651				0.747
With B symptom	0.408				0.230
IPI > 2	0.807				0.745
GCB (reference non-GCB)	0.270				0.281
DE	0.360				0.304
DH	0.057			0.072	0.041			0.057
Not received CR	0.007	3.070	1.419-6.643	0.004	0.013	3.095	1.371-6.987	0.007

DH: double hit; DE: double-protein-expression; * P value was calculated by COX regression and p < 0.05 regarded significant.

Data availability statement

The authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.